Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co Days Payable Chart
Qinghai Spring Medicinal Resources Technology Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Qinghai Spring Medicinal Resources Technology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qinghai Spring Medicinal Resources Technology Co Days Payable vs Drug Manufacturers Industry
Qinghai Spring Medicinal Resources Technology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) has a Days Payable of 17.95 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. This is 40% above median its historical median of 12.79. Over the past decade, Qinghai Spring Medicinal Resources Technology Co's Days Payable has ranged from 6.53 to 226.15. According to the industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #923 out of 927 companies in the Drug Manufacturers industry, placing it in the top 99.6%.
Is Qinghai Spring Medicinal Resources Technology Co's Days Payable too high?
Qinghai Spring Medicinal Resources Technology Co's current Days Payable of 17.95 is 40% above median its 10-year median of 12.79. Over the past 10 years, this metric has ranged from a low of 6.53 to a high of 226.15. The Drug Manufacturers industry median Days Payable is 90.38. Qinghai Spring Medicinal Resources Technology Co's value of 17.95 is 80.1% below this industry median. Based on the distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #923 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Qinghai Spring Medicinal Resources Technology Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qinghai Spring Medicinal Resources Technology Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Qinghai Spring Medicinal Resources Technology Co ranks #923 out of 927 companies for Days Payable. This places Qinghai Spring Medicinal Resources Technology Co in the lower half of its industry. The industry median Days Payable is 90.38. Qinghai Spring Medicinal Resources Technology Co's value of 17.95 is 80.1% below this benchmark. Historically, Qinghai Spring Medicinal Resources Technology Co's own Days Payable has ranged from 6.53 to 226.15 over the past decade. While the company's 10-year median is 12.79 vs. the industry median of 90.38, Qinghai Spring Medicinal Resources Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qinghai Spring Medicinal Resources Technology Co's current Days Payable of 17.95 is 80.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Qinghai Spring Medicinal Resources Technology Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qinghai Spring Medicinal Resources Technology Co's current Days Payable is 17.95, which is 40% above median its own 10-year median of 12.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qinghai Spring Medicinal Resources Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥4.20 — trading 28.2% below its estimated fair value. The current Days Payable is 17.95, which is 40% above median its 10-year median of 12.79 and 80.1% below the Drug Manufacturers industry median of 90.38. Qinghai Spring Medicinal Resources Technology Co's overall GF Score™ is 68/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Qinghai Spring Medicinal Resources Technology Co (SHSE:600381), the current Days Payable is 17.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qinghai Spring Medicinal Resources Technology Co (SHSE:600381) Overvalued in 2026?
Based on GuruFocus' analysis, Qinghai Spring Medicinal Resources Technology Co stock appears to be undervalued.
The current stock price of ¥4.20 is trading 28.2% below its estimated GF Value™ of ¥5.85.
GuruFocus considers Qinghai Spring Medicinal Resources Technology Co to be Modestly Undervalued.
Key valuation signals for SHSE:600381:
Days Payable: 17.95 (40% above median its 10-year median of 12.79)
GF Value™: ¥5.85 vs. price of ¥4.20 (28.2% below fair value)
Industry Position: 80.1% below the Drug Manufacturers median (#923 of 927)
No single metric tells the full story. See the SHSE:600381 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qinghai Spring Medicinal Resources Technology Co Business Description
Qinghai Spring Medicinal Resources Technology Co Ltd is a China-based company that principally engaged in the integrated development, utilization, production, sales, and consulting services of the natural advantageous resources on the Qinghai-Tibet plateau, as well as the development and utilization of other biological resources. The Company's main products are the cordyceps sinensis series products under the Verygrass brand, which includes cordyceps sinensis pure powder tablet, processed cordyceps sinensis, and raw cordyceps sinensis.
68GF Score
Get the complete analysis for SHSE:600381
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600381 has been successfully added to your 
